Ultragenyx Pharmaceutical Inc. (RARE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated August 4, 2026, announces the financial results for the three months ended June 30, 2026. The filing serves to incorporate a press release (Exhibit 99.1) detailing the Company's operational and financial performance for the second quarter of 2026.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data. Consequently, the following metrics are not available in this document:
- Revenue and profit figures
- Cash flow and liquidity positions
- Profit margins
- Debt levels
Investors must refer to the attached Press Release (Exhibit 99.1) for these specific values.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. It only confirms the issuance of results for the quarter ended June 30, 2026.
Guidance, Outlook, and Risks
The document does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies and unusual items. These disclosures are contained within the referenced Press Release (Exhibit 99.1), which is furnished but not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Key Facts for Investor Verification
- Reporting Date: Results cover the three months ended June 30, 2026.
- Data Source: All financial figures and strategic commentary are located in Exhibit 99.1 (Press Release), not in the 8-K text itself.
- Legal Status: The information in the press release is not incorporated by reference into other filings unless expressly stated.
- Signatory: The report was signed by Howard Horn, Executive Vice President and Chief Financial Officer.